• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Abiomed, Inc.

    FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    First Patients in the World Treated with Impella RP Flex with SmartAssist
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    First Patient in Japan Treated with Impella 5.5 with SmartAssist
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Abiomed to Present at Upcoming Investor Conferences
    From Abiomed, Inc.
    Via Business Wire
    Tickers ABMD
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.